In the United States, cheaper medicines exist but remain out of reach for many patients due to the influence of middlemen in the pharmaceutical supply chain. According to an opinion piece by Robert Zirkelbach published on July 15, 2026, patients and their doctors are not the final decision-makers when it comes to accessing these more affordable medications. The article highlights how intermediaries in the drug distribution process are profiting at the expense of patients, limiting their ability to obtain lower-cost treatment options.

This situation underscores ongoing challenges in the healthcare system where cost-saving opportunities are hindered by complex market dynamics and third-party actors.

Sources: